SignalFDA/Bio
Amgen's cancer drug combo cut death risk by 58% in lung cancer trial
Amgen's cancer drug combo cut death risk by 58% in a lung cancer trial.
Context
What happened: Amgen's Imdelltra combined with AstraZeneca's Imfinzi cut death risk by 58% versus Imfinzi alone in a lung cancer trial.
Key numbers: Median survival was 21.1 months with the combination versus 12.7 months for Imfinzi alone. Death risk reduction was 58%.
Why it matters: The trial result points to a survival advantage for the combination over Imfinzi alone in lung cancer, a comparison the content presents as the basis for the 58% figure.
What changed
Amgen's Imdelltra combined with AstraZeneca's Imfinzi cut death risk by 58% versus Imfinzi alone in a lung cancer trial.
Why it matters
The trial result points to a survival advantage for the combination over Imfinzi alone in lung cancer, a comparison the content presents as the basis for the 58% figure.